On December 21, Guangshengtang (300436.SZ) said on the investor interactive platform on December 21 that at present, the company's anti-coronavirus oral small-molecule 3CL protease inhibitor, the innovative drug Taizhongding (atetetevir GST-HG171 combined with ritonavir tablets) has been approved for marketing. Among them, attetevir GST-HG171 is a highly active and highly selective oral 3CL protease inhibitor that can exert a broad spectrum of inhibitory effects on the coronavirus and its derived mutated strains. Clinical study results confirm that Thailand and China can significantly shorten the clinical recovery time of COVID-19 infected patients, significantly reduce viral load, are safe and effective, and are currently the only anti-COVID-19 drugs that have been approved for marketing or accepted for marketing or accepted to be marketed or accepted, showing excellent efficacy and statistically different data on the XBB variant population in key registered clinical studies. The company will continue to expand various sales channels. As long as it is within the scope permitted by policies and regulations, it will provide as much access to medication as possible, including medical terminals, Internet hospitals, and online platforms.